Taibang Biological Group

What Taibang Biological Group does

Taibang Biological Group is a privately held Chinese biopharmaceutical company founded in 2002 and headquartered in Beijing, with operations built around the development, manufacture, and sale of plasma-derived products and complementary medical devices. The company originated from the Shandong Provincial Biological Products Research Institute and grew through a series of acquisitions (Shandong Taibang, Guizhou Taibang, Xi'an Huitian, and Tianxinfu) into a vertically integrated plasma products platform with manufacturing facilities in Shandong, Guizhou, and Beijing. After a Nasdaq listing from 2009 to 2021 under the ticker CBPO, the company was taken private in April 2021 in an approximately $4.8 billion transaction and is now incorporated in the Cayman Islands as China Biologic Products Holdings, Inc.

The core product portfolio comprises 10 plasma-derived products across three categories (human albumin, human immunoglobulins for IV, IM, and specific indications including tetanus, rabies, and hepatitis B, and human coagulation factors VIII, IX, fibrinogen, and prothrombin complex) in over 20 specifications, plus a medical device line including the DuraFrame® artificial dura, DuraGide® artificial spinal dura, T-Frame dual-layered sutureless dura, NervElite® nerve conduit, Teno Wrap® anti-adhesion membrane, NeurObserver® tissue dilator, and the RETRUEGEN placenta polypeptide injection. Manufacturing relies on advanced plasma fractionation technology with proprietary 20nm virus filtration and caprylate/chromatography purification methods, supported by over 100 plasma product patents and more than 20 medical device patents.

The business model is a B2B direct-sales operation selling into more than 600 hospitals and disease control centers across China through specialized sales teams for each product category, with an additional international business channel. Revenue is generated through one-time product sales of plasma derivatives and devices to healthcare institutions. The company has a 1,001-5,000 employee base and is led by a senior management team with 25-40+ years of industry experience, including CEO Wu Kun and Honorary Chairman Pang Guangli. In August 2022 it raised $300 million from ADIA and GIC to fund expansion and R&D, and in mid-2026 it participated as an industrial investor in Zhipingfang's approximately $700 million round tied to embodied AI.

Name

Taibang Biological Group

Legal name

China Biologic Products Holdings, Inc.

Website

https://en.chinabiologic.com

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Taibang Biological Group is a privately held Chinese biopharmaceutical company that manufactures and sells plasma-derived products (albumin, immunoglobulins, coagulation factors) and surgical medical devices, selling directly to over 600 hospitals and disease control centers across China.

Ownership category

akta.pro rank

Product category

Plasma-derived Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Plasma-derived biopharmaceuticals
• Human albumin products
• Intravenous immunoglobulin
• Coagulation factor therapy
• Surgical medical devices

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Plasma-derived Products Sales: Sale of plasma-derived products including human albumin, human immunoglobulin, and human coagulation factors to hospitals and disease control centers
2. Medical Devices Sales: Sale of medical devices including artificial dura, artificial spinal dura, artificial nerve conduits, anti-adhesion membranes, and tissue dilators
3. Placenta Polypeptide Products: Sale of placenta polypeptide injection products (RETRUEGEN) for medical applications

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Taibang Biological Group develops, manufactures, and sells plasma-derived biopharmaceutical products (including human albumin, human immunoglobulins, and human coagulation factors) and medical devices (including artificial dura mater, artificial nerve conduits, anti-adhesion membranes, and tissue dilators). The company operates three manufacturing bases in China and sells directly to over 600 hospitals and disease control centers through dedicated product-line sales teams.

Product overview

Taibang Biological Group is a leading Chinese biopharmaceutical company providing a comprehensive portfolio of plasma-derived products and medical devices. The company operates two main product segments: plasma-derived products covering 10 products across 3 categories (human albumin, human immunoglobulin, and human coagulation factors) in more than 20 specifications, and medical devices including artificial dura, nerve conduits, anti-adhesion membranes, and tissue dilators. The plasma-derived products include Human Albumin, Human Immunoglobulin (pH4) for IV injection, Human Fibrinogen, Human Prothrombin Complex, Human Tetanus/Rabies/Hepatitis B Immunoglobulins, and Human Coagulation Factors VIII and IX. The medical device portfolio includes Artificial Dura (DuraFrame®), Artificial Spinal Dura (DuraGide®), Dual-layered Sutureless Artificial Dura (T-Frame), Artificial Nerve Conduit (NervElite®), Anti-adhesion Membrane for Tendons (Teno Wrap®), Disposable Tissue Dilator (NeurObserver®), and Placenta Polypeptide Injection (RETRUEGEN).

Differentiator

Problem solved

Functional benefit

Brands

• DuraGide®: Artificial Spinal Dura for surgical repair of spinal dura
• DuraFrame®
• NervElite®
• Teno Wrap®
• NeurObserver®
• T-Frame
• RETRUEGEN

Products and services

• Human Albumin
• Human Immunoglobulin (pH4) for Intravenous Injection Intravenous immunoglobulin product for treating primary immunoglobulin G deficiency, secondary immunodeficiency, and autoimmune diseases such as immune thrombocytopenia and Kawasaki disease. Supplied as 5g/bottle (10%, 50ml). For hospitals and clinical specialists.
• Human Immunoglobulin (pH4) for Intravenous Injection (Legacy Specification) Intravenous immunoglobulin product for primary immunoglobulin deficiency, secondary immunodeficiency, and autoimmune diseases. Available in 1.25g, 2.5g, and 5g bottle specifications. For hospital and clinical use.
• Human Fibrinogen Plasma-derived fibrinogen for treating congenital fibrinogen deficiency and acquired fibrinogen deficiency due to severe liver damage, cirrhosis, DIC, postpartum hemorrhage, and surgical trauma. Supplied as 0.5g/bottle with 48-month validity. For hospital use.
• Human Prothrombin Complex Plasma-derived prothrombin complex for treating congenital and acquired Factor II, VII, IX, X deficiency including Hemophilia B, anticoagulant overdose, vitamin K deficiency, and liver disease-related coagulation disorders. Supplied as 300IU/bottle.
• Human Tetanus Immunoglobulin Plasma-derived tetanus immunoglobulin for prevention and treatment of tetanus, particularly suitable for patients with allergic reactions to tetanus antitoxin (TAT). Supplied as 250IU/2.5ml/bottle.
• Human Rabies Immunoglobulin Plasma-derived rabies immunoglobulin for passive immunization of patients bitten by rabid animals. Available in 100IU, 200IU, and 500IU bottle specifications.
• Human Coagulation Factor VIII Plasma-derived coagulation factor VIII for treating Hemophilia A and acquired Factor VIII deficiency bleeding symptoms and surgical bleeding. Available in 200IU and 300IU bottle specifications with diluent.
• Human Immunoglobulin Plasma-derived immunoglobulin for prevention of measles and infectious hepatitis, and enhanced efficacy against severe bacterial and viral infections when combined with antibiotics. Available in 150mg and 300mg bottle specifications.
• Human Hepatitis B Immunoglobulin Plasma-derived hepatitis B immunoglobulin for prevention of hepatitis B infection in newborns of HBsAg-positive mothers, accidentally infected individuals, and close contacts with hepatitis B patients. Available in 100IU, 200IU, and 400IU bottle specifications.
• Human Coagulation Factor IX Plasma-derived coagulation factor IX for treating bleeding in patients with Factor IX deficiency (Hemophilia B). Supplied as 500IU/10ml/bottle with approval number S20200014.
• Dual-layered Sutureless Artificial Dura (T-Frame) Dual-layered artificial dura mater with loose layer and dense layer structure for brain membrane repair, providing isolation, protection, and degradable absorption. For neurosurgical applications.
• Artificial Dura (DuraFrame) Artificial dura mater for surgical repair of various brain membrane damage and defects. Features a sutureless design enabling simplified surgical procedures, in-situ reconstruction, and synchronous absorption, based on over 10 years of clinical application in China. For neurosurgeons and hospitals.
• Artificial Nerve Conduit (NervElite) Collagen-based nerve conduit product for peripheral nerve repair and protection following nerve injury, compression, release, and anastomosis. Suitable for nerve gaps within 15mm through microsurgical technique. For surgical specialists.
• Anti-adhesion Membrane for Tendons (Teno Wrap) Biodegradable anti-adhesion membrane for tendon repair following rupture, displacement, transplant anastomosis, and tendon contusion or release procedures. Features anti-adhesion, promotion of repair, and degradable properties. For orthopedic and hand surgeons.
• Disposable Tissue Dilator (NeurObserver) Disposable tissue dilator for medical procedures. For surgical specialists and hospitals.
• Artificial Spinal Dura (DuraGide) Artificial spinal dura mater for surgical repair of spinal dura defects and damage. For spinal surgeons and hospitals.
• Placenta Polypeptide Injection (RETRUEGEN) Placenta polypeptide injection product for clinical applications, used as an important medication for prevention and treatment of novel coronavirus pneumonia. For hospitals and clinical use.

Quantifiable outcome

• Over 600 hospitals and disease control centers served through direct sales network
• +2 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Tianxinfu (Beijing) Medical Devices Co., Ltd.coreStrategic or Co-development Partner · 1 January 2019Taibang achieved 100% ownership of Tianxinfu in 2019, having acquired 80% stake in 2018. Tianxinfu specializes in medical devices including artificial dura, nerve conduits, and tissue repair products.
• Guizhou Taibang Biological Products Co., Ltd.coreStrategic or Co-development Partner · 1 January 2016Taibang acquired 100% control of Guizhou Taibang in 2016, having initially taken controlling stake (68%) in 2008. Guizhou Taibang is a plasma product manufacturing facility.
• Xi'an Huitian Blood Products Co., Ltd.minorStrategic or Co-development Partner · 1 January 2009Taibang acquired 35% equity stake in Xi'an Huitian in 2009, expanding its plasma product manufacturing footprint.

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Hualan Biological Engineering: One of China's largest plasma-derived product manufacturers, producing human albumin, IVIG, and coagulation factors. Closest direct competitor to Taibang in the Chinese plasma fractionation market with overlapping hospital customer base.
• Octapharma: Privately held global plasma fractionator with comparable product breadth across coagulation factors, immunoglobulins, and albumin. Closely comparable business model and end-market orientation to Taibang.
• LFB (Laboratoire Français du Fractionnement et des Biotechnologies): French state-backed plasma fractionator producing albumin, immunoglobulins, and coagulation factors. Comparable scale, product mix, and fractionation-technology profile to Taibang.
• Shanghai RAAS Blood Products: Major Chinese plasma fractionator with a broad portfolio of plasma-derived therapeutics including albumin and immunoglobulins. Directly competes with Taibang for hospital contracts and plasma collection stations across China.
• Kedrion Biopharma: European-headquartered plasma fractionator producing albumin, IVIG, and coagulation factor products for global markets. Similar privately-held profile and product portfolio structure to Taibang.

Broad incumbents

• Integra LifeSciences: Global medical device company with a leading neurosurgery portfolio including artificial dura substitutes (DuraGen) that compete directly with Taibang's DuraFrame and DuraGide products. Relevant comparable for Taibang's Tianxinfu medical device franchise.
• Grifols: Global leader in plasma-derived therapies with manufacturing scale and fractionation technology well beyond Taibang's. Competes indirectly in Asia-Pacific and serves as the primary global benchmark for fractionation economics and plasma sourcing.
• CSL Behring (CSL Limited): Largest global plasma fractionator with leading albumin, IVIG, and specialty coagulation factor franchises. Operates Asia-Pacific commercial channels that overlap with Taibang's expansion ambitions.

Emerging players

• Boya Bio-Pharmaceutical: Chinese plasma-derived product manufacturer with growing albumin and immunoglobulin capacity. An emerging domestic competitor to Taibang with overlapping customer segments.

Regional players

• Tiantan Biological Products: China-based blood products and vaccine manufacturer with plasma-derived product lines that overlap Taibang's albumin and immunoglobulin categories. Competes primarily in the domestic Chinese market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/china-biologic-products-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries4 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taibang Biological Group